Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.68 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.68 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.68 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stanolone SCHEMBL619535 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL3486722 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL15963544 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL24684703 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL1570704 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL24410503 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL9340073 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL333299 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL21442439 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL27379 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220206018-A1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF SEX HORMONE DISORDERS | FUNCTION PROMOTING THERAPIES LLC (US) | 2022-06-30 | — | — | US | disclosed |
| EP-2965085-B1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | FUNCTION PROMOTING THERAPIES LLC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200174026-A1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | FUNCTION PROMOTING THERAPIES LLC (US) | 2020-06-04 | — | — | US | disclosed |
| US-10386375-B2 | Methods and systems for the diagnosis and treatment of androgen disorders | FUNCTION PROMOTING THERAPIES LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160018420-A1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | FUNCTION PROMOTING THERAPIES, LLC (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2965085-A1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | Function Promoting Therapies, LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138026-A1 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | FUNCTION PROMOTING THERAPIES, LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-1807118-B1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HARBOR BIOSCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2471536-A1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Harbor BioSciences, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2000066613-A1 | BONE TARGETING AGENTS FOR OSTEOPOROSIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | SHBG 40/4885GPBAR1 213/4885CYP19A1 22/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | SHBG 4170/4885GPBAR1 2200/4885CYP19A1 4139/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | SHBG 145/4885GPBAR1 264/4885CYP19A1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.